Products for Research Use Only
RegisterLogin

Murrayafoline A

CAT: 0804-HY-W100287-01Size: 25 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-W100287-01Size:25 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Murrayafoline A is a carbazole alkaloid that can be extracted from Murraya tetramera. Murrayafoline A directly targets Specificity protein 1 (Sp1), thereby inhibiting NF-κB and MAPK signaling pathways. Murrayafoline a induces a G0/G1-phase arrest in platelet-derived growth factor (PDGF) -stimulated vascular smooth muscle cells. Murrayafoline A attenuates the Wnt/β-catenin pathway by promoting the degradation of intracellular β-catenin proteins. Murrayafoline A enhances the contraction of rat ventricular myocytes and L-type calcium current by activating protein kinase C. Murrayafoline A inhibits LPS -induced neuroinflammation in vivo. Murrayafoline A can be used for the study of inflammation, vascular complications and colon cancer[1][2][3][4].
CAS Number
4532-33-6
UNSPSC
12352005
Hazard Statement
H341, H351, H413
Target
IKK; Interleukin Related; JNK; NF-κB; p38 MAPK; Wnt; β-catenin
Type
Natural Products
Related Pathways
Immunology/Inflammation; MAPK/ERK Pathway; NF-κB; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/murrayafoline-a.html
Purity
99.73
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CC1=CC2=C(C(=C1)OC)NC3=CC=CC=C23
Molecular Formula
C14H13NO
Molecular Weight
211.26
Precautions
H341, H351, H413
References & Citations
[1]Li CH, et al. Natural carbazole alkaloid murrayafoline A displays potent anti-neuroinflammatory effect by directly targeting transcription factor Sp1 in LPS-induced microglial cells. Bioorg Chem. 2022 Dec;129:106178. |[2]Han JH, et al. Murrayafoline A Induces a G0/G1-Phase Arrest in Platelet-Derived Growth Factor-Stimulated Vascular Smooth Muscle Cells. Korean J Physiol Pharmacol. 2015 Sep;19 (5) :421-6. |[3]Choi H, et al. Murrayafoline A attenuates the Wnt/beta-catenin pathway by promoting the degradation of intracellular beta-catenin proteins. Biochem Biophys Res Commun. 2010 Jan 1;391 (1) :915-20. |[4]Chidipi B, et al. Enhancement of contraction and L-type Ca (2+) current by murrayafoline-A via protein kinase C in rat ventricular myocytes. Eur J Pharmacol. 2016 Aug 5;784:33-41.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Natural Products
Clinical Information
No Development Reported

Alternative Products

CatalogName
GTR19228871-01Murrayafoline A

Popular Products